Evaluate DNLI stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in DNLI? | Glauxie AI

Q: What are the risks of investing in DNLI?

Denali Therapeutics Inc. (DNLI) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Ryan J. Watts. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2... Employees: 30,000.

Q: How much debt does DNLI have?

Review DNLI total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is DNLI a good long-term investment?

Evaluate DNLI as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in DNLI?

🦉

Denali Therapeutics Inc. (DNLI)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEORyan J. Watts

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in...

Key Executives

Name	Title
Alexander O. Schuth	Co-Founder, Chief Financial Officer, Chief Operating Officer & Secretary
Chris Walsh	General Counsel
Cindy Dunkle	Chief People Officer
Dana Andersen	Chief Technical and Manufacturing Officer
Joe Lewcock	Chief Scientific Officer
Katie Peng	Chief Commercial Officer

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

DNLI Profile Financials

Is DNLI stock safe? How much debt does DNLI have? Is DNLI a good long-term investment?